anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study is to test the safety and effectiveness of the medicine belatacept (Nulojix®) in preventing antibodies from forming in people with a failing kidney transplant. Kidney transplant patients take immunosuppression medicines to prevent kidney rejection. When a kidney transplant begins to fail, the immunosuppression medicines are slowly weaned. Once dialysis is started, the immunosuppressant medicines are usually stopped. After immunosuppression is stopped, some people form antibodies. Antibodies are proteins that the immune system makes to protect against harmful foreign substances like bacteria, viruses, or foreign tissues, like a transplant. High levels of antibodies can make it harder to find a kidney donor for that person.

Participants will be randomized into one of the two treatment groups. One group will continue taking their current immunosuppression medicines. The people in the treatment group will be switched to belatacept (Nulojix®). Belatacept (Nulojix®) is an immunosuppression medicine that is approved by the U.S. Food and Drug Administration (the FDA) to prevent rejection in kidney transplant. Participants will stop taking calcineurin inhibitors (either cyclosporine or tacrolimus) or sirolimus but will keep taking other immunosuppression medicines like Cellcept (MMF) or azathioprine (Imuran) and prednisone. These medicines will be slowly weaned and will be stopped if the participant has to start dialysis. Participants will continue taking belatacept (Nulojix®), even while on dialysis.

The study team will test both groups to see how many people in each group develop antibodies.
Substances for use as vehicles in suppositories.. F3A. Are produced as follows. Solid fats, consisting of esters of fatty acids (12-20 carbon atoms) with polyalcohols such as glycerol, are esterified with monocarboxylic acids (1-8 carbon atoms) so as to reduce the hydroxyl index of 10 and pref. to zero. Originally, substances based on cocoa-butter were used for this purpose; however, these were unstable and the desirable close control of melting-point was not obtainable. Fats of hydroxyl index 10-65 have been tried, but these reacted chemically with the medicaments. Attempts to esterify the free -OH groups with glycerol give breakable solids. The products of this invention are stable, have a controlled melting point, are unreactive and are not fragile.
FIELD: organic chemistry, biology, pharmacy. SUBSTANCE: invention elates to novel substituted of bis-indolimaleimide of the formula (I)   and their pharmaceutically acceptable salts also where R 1  means hydrogen atom; R 2  means methyl; or R 1  means methyl and R 2  means hydrogen atom; or R 1  mean hydroxymethyl and R 2  means methyl. Invention relates also to pharmaceutical composition eliciting an antiproliferative activity and comprising compound of the formula (I) and pharmaceutically acceptable carrier. Invention provides preparing the novel compound designated for inhibition of cells proliferation. EFFECT: valuable biological and medicinal properties of compounds. 5 cl, 8 tbl
1. Technical Result Regulation of expression of human bones morphological protein BMP-7.                  2. Essence A method for exploring low molecular weight compounds, which regulate positively or negatively the expression of human BMP-7 with reference to a reporter activity by using 5' upstream region gene containing the human BMP-7 promoter and an animal cell introduced with the vector that has been connected to an appropriate reporter gene. The low molecular weight compounds and their derivatives obtained by the present method have morphogenetic activity and inhibiting activity for bone and cartilage through the expression of the human BMP-7 and are useful as preventive or therapeutic agents for cartilage and bone diseases. Furthermore, the low molecular weight compounds and their derivatives are useful as therapeutic agents for kidney diseases.         3. Field of Application Medicine.
The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional, and cognitive state, compliance, concomitant medications and side effects if any, among patients on NeuroAiD. Participation is voluntary. Data collected are similar to information obtained during standard care and are prospectively entered by the participating physicians at baseline (before initialization of NeuroAiD) and during subsequent visits. The follow up visits are timed with clinical appointments. Anonymized data will be extracted and collectively analyzed. Initial target sample size for the registry is 2000.
Expert teachers will be identified based on years as faculty, number of supervised procedures, prior teacher awards, and participation in IBP teaching at international conferences. Novice teachers will include those that have performed less than 50 CVCs. Teachers will supervise 3 simulated central venous catheters (CVC) insertions with increased complexity while wearing an eye tracking device.
Cholera remains a serious public health problem worldwide. Provision of safe water and food, establishment of adequate sanitation, and implementation of personal and community hygiene constitute the main public health interventions against cholera. These measures cannot be implemented fully in the near future in most cholera-endemic areas. A safe, effective, and affordable vaccine would be a useful tool for cholera prevention and control.The World Health Organization recently recommended that the newer generation cholera vaccines be considered in certain endemic and epidemic situations, but indicated that demonstration projects are needed to provide more information about the costs, feasibility, and impact of using these vaccines. Starting in the mid-1980s, following technology transfer from Prof Jan Holmgren in Sweden, Vietnamese scientists at the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi developed and produced an oral, killed cholera vaccine for the country's public health programs (10). Since licensure of the oral cholera vaccine in Vietnam, more than 5 million doses have been administered without any report of serious adverse events.

The vaccine is produced according to recommended WHO guidelines (6) at the NIHE's newly privatized arm, the Company for Vaccine and Biological Production No. 1 (VABIOTECH) in Hanoi. Recently the vaccine was reformulated in order to comply with WHO standards to further internationalize this vaccine. Phase II trials of this reformulated vaccine have been performed among 148 adults in SonLa,Vietnam (18) and among 100 adults and 100 children in Kolkata, India. Results from these trials reveal that the vaccine is safe and immunogenic.

A double-blind randomised phase III trial of the reformulated oral killed bivalent cholera vaccine in an urban slum site in Kolkata is proposed by the National Institute of Cholera and Enteric Diseases (NICED) in collaboration with the International Vaccine Institute (IVI). The IVI has negotiated an agreement between VABIOTECH and Shantha Biotechnics PVT LTD for the vaccine and placebo to be used during the trial. VABIOTECH will produce bulk oral killed bivalent cholera vaccine under quality control conditions to be supervised by IVI staff. Shanta will purchase bulk vaccine from VABIOTECH, fill and finish the bulk vaccine, and obtain regulatory clearance for use of the vaccine in the phase III trial. Shanta will purchase the bulk placebo agent for use in the trial from IVAC (also in Vietnam) and Shanta will fill and finish the placebo and obtain regulatory clearance for use of the placebo in the phase III trial. Shanta will later obtain the technology for future production of the oral killed bivalent cholera vaccine. The results of this trial will pave the way for the use of this vaccine in India and other cholera-endemic areas.
This protocol is not designed as a treatment protocol. Patients enrolled on this study will be treated according to the treating physician's plan of care, independent of enrollment into the study. Once enrolled, the physician may proceed with the appropriate plan of care during the period of specimen analysis if indicated. Upon return of the results, therapy may or may not be altered based upon the patient's pathology, pertinent medical and treatment history, imaging studies, available clinical trials, and on the CLIA validated clinical molecular profiling results. Regardless of the results, the patient will be offered a treatment selected on an empirical basis by the treating physician at the individual site. All patients enrolled in the study will be followed for clinical outcome. Clinical molecular profiling results will expire 14 weeks following the date the Foundation One report is received. No investigational agents will be administered as part of this study. However, patients may be referred to open clinical trials based on the results of profiling. Patients referred for clinical trial may receive investigational agents under a separate clinical trial in accordance with the written protocol for which they are subsequently enrolled. All anti-neoplastic drugs used while participating in this study, whether used on-label or off-label, will be administered to the patient by the route of administration published in the FDA approved package insert. In addition, the dosing of the agent (including dose modifications) will be calculated based upon what is published in the FDA approved package insert.
The questionnaire form is included in the section on COVID-19. 2nd question; They will mark the answer "Yes" to the question "Have you been diagnosed with COVID-19?" 5th question; Individuals who answer "No" to the question "Have you been subjected to discriminatory behaviors by your environment because you were a healthcare worker during the COVID-19 pandemic process?" Will move on to the 11th question in the same section.
PURPOSE:To produce highly pure tocopheryl retinoate useful as an ingredient for medicines such as gastrointestinal ulcer therapeutic agents and skin disease therapeutic agents or for cosmetics in a high yield, and to enable the employment of a wide range of solvents in the reaction operations. CONSTITUTION:Retinoic acid (vitamin A acid) is reacted with trifluoroacetic anhydride and subsequently with tocopherol. The reaction product is subjected to a hydrolysis condition in the aqueous solution of an aqueous basic substance such as an inorganic base, e.g. NaOH, KOH, Na2CO3 or K2CO3, an organic amine, e.g. dimethylamine, preferably ammonia, and purified. The hardly separable by-product, tocopheryl trifluoroacetate, is selectively hydrolyzed by a simple treatment capable of being performed in the same reaction container as for the esterification reaction without requiring a special installation and device, thus producing the highly pure tocopheryl retinoate in a good yield.
Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
FIELD: medicine, surgery, anesthesiology. SUBSTANCE: invention relates to anesthesiological protection of brain in patients to be operated with brain tumors, chronic intracranial hematomas, aneurysm of intracerebral vessels. Method involves the use of synthetic opioid peptide dalargin in combination with different anesthetics. Dalargin is administrated as a bolus by intravenous route at the dose 1 mg for each 30 min during operation and beginning from the stage of dura matter opening. EFFECT: enhanced effectiveness of brain protection. 2 tbl, 2 ex
Controversy exists regarding the relevance of changes in gonadal steroids for midlife onset depressions. The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols that examine the role of gonadal steroids in depressions occurring during the perimenopause and for the collection of natural history data. Women in this protocol will undergo an evaluation which may include: a psychiatric diagnostic interview; rating scales; a medical history; a physical exam; blood and urine laboratory evaluation; and a request for medical records. The data collected may also be linked with data from other perimenopausal depression protocols (e.g., DNA, psychophysiology tests, treatment studies, etc.) for the purposes of better understanding the diagnosis, pathophysiology, and treatment response of women with depression during the perimenopause.Upon conclusion of the screening process, participants will either be offered entry into a research protocol and will sign the appropriate informed consent, or will be considered not appropriate for participation in research and will be referred back into the community. The second purpose of this protocol is to permit the identification of premenopausal women who are followed longitudinally through the menopause transition in an effort to confirm the association of depression onset with change in reproductive endocrine function. This protocol, then, serves as a screening and evaluation protocol to recruit subjects who are characterized with standard measures in this protocol and then offered participation in related studies.
In some embodiments, the present disclosure provides methods for stimulating a subject's immune system. Particular methods provide a tumor specific immune response by injecting a tumor with a magnetorheological fluid and applying a magnetic field to the tumor. The immune response can be used to treat disseminated tumors or metastatic cells. Further methods induce a general immune response, such as by treating a section of tissue, such as healthy tissue, with a magnetorheological fluid and applying a magnetic field to the treated tissue. The immune response can be used to treat illness or disease or to enhance the effect of a therapeutic agent. In particular examples, the disclosed methods are used to enhance the effect of immuno stimulants. Also provided are methods for causing necrosis of a cell mass, such as a tumor, by injecting a magnetorheological fluid into a section of tissue and applying a magnetic field to the tissue.
Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
A hair-increasing fiber powder packaging bottle with a manually adjustable fiber amount includes a packaging bottle body. The packaging bottle body includes a bottle cap, a top screw cap, a lower cap body, a filter plug, and a bottle body. The top screw cap is mounted to a bottom end of the bottle cap. A deformation support and a non-slip surface are disposed on two sides of the top screw cap. A deformation space is disposed on an inner side of the deformation support. A surface of the top screw cap is provided with a discharge hole. A gear projection is mounted to one side of the top screw cap. A connecting projection is disposed on a side edge of the top screw cap. A sealing boss is disposed on a top end of the top screw cap.
The purpose of this study is to identify important endpoints and outcomes for use in pediatric trials of acute pain therapeutics in children who are 0 to \<3 years of age from a clinician's perspective. To identify these endpoints and outcomes the investigators will conduct remote qualitative concept elicitation interviews with 27 clinicians who treat pediatric patients. These interviews will include verbal consent to participate, a demographics questionnaire, and a semi-structured interview which will last approximately one hour. Interview questions will address the participant's professional experience recognizing and managing pain in children between 0 and 3 years of age. Interviews will be audio recorded and transcribed with the participant's permission. Transcripts and notes will be coded and analyzed. This is a minimal risk study; the investigators are only using standard interview procedures and are not collecting any protected health information from participants. While the investigators do not believe that any information collected would jeopardize the personal or professional standing of participants, all information will be kept strictly confidential per Good Clinical Practice guidelines.
METHODOLOGY This descriptive, cross-sectional study was conducted at Department of Surgical Oncology of a tertiary care hospital between June 2020 and August 2020. The study centre has a 1,200-bed capacity and the surgical oncology clinic has a 30-bed capacity. A total of 57 women who were scheduled for elective mastectomy for breast cancer were included. Inclusion criteria were as follows: women aged ≥18 years, hospitalization 6 hours prior to surgery, American Society of Anesthesiologists (ASA) Class I-III, having no chronic pain or alcohol and/or substance abuse, having no cognitive impairment, no need for mechanical ventilation, having a confirmed diagnosis of breast cancer, and being scheduled for mastectomy. Prior to study, all patients were informed about the nature of the study and a written informed consent was obtained. The study protocol was approved by the institutional Non-Interventional Clinical Research Ethics Committee (No: 15.05.2020/99). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Preoperative and postoperative data within 48 hours were collected via face-to-face interviews. The Patient Assessment Form, which was developed in accordance with the previous studies in the literature, was used to collect data including age and body mass index (BMI) pre- and postoperatively. For the postoperative evaluation, the four-item, simplified Apfel Risk Scoring System was used. It is a valid tool which assesses PONV and/or motion sickness, non-smoking status, and postoperative use of opioids. Accordingly, 0-1 indicate low, 2 indicate moderate, and ≥3-4 indicate high risk for PONV \[12\]. In our study, PONV was evaluated using the Patient Assessment Form at 0, 2, 4, 8, 24, and 48 hours as "Yes/No" scoring.

Statistical analysis was performed using the SPSS version 22.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were expressed in mean ± standard deviation (SD), median (min-max) or number and frequency, where applicable. The chi-square test was used to evaluate relationship between categorical variables. The Mann-Whitney U test (Z table values) was performed to compare two independent groups which did not meet the normal distribution. The continuity correction and Fisher exact test were used to examine the relationship between two quantitative variables. The independent samples t-test (t table values) was used to compare two independent groups which met the normal distribution. A p value of \<0.05 was considered statistically significant.
Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
Increased biosynthesis or underexcretion of uric acid (UA or urate) in the body ultimately leads to the development of hyperuricemia. Epidemiological studies indicate that hyperuricemia is closely associated with the occurrence of various diseases such as gout and cardiovascular diseases. Currently, the first-line therapeutic medications used to reduce UA levels primarily include xanthine oxidase (XO) inhibitors, which limit UA production, and urate transporter 1 (URAT1) inhibitors, which decrease urate reabsorption and enhance urate excretion. Despite significant progress in urate-lowering therapies, long-term use of these drugs can cause hepatorenal toxicity as well as cardiovascular complications. Therefore, there is an urgent need for novel anti-hyperuricemic agents with better efficacy and lower toxicity. This perspective mainly focuses on the current research progress and design strategy of anti-hyperuricemic agents, particularly those targeting XO and URAT1. It is our hope that this perspective will provide insights into the challenges and opportunities for anti-hyperuricemic drug discovery.
Participants will receive azacitidine on days 1-7 and venetoclax daily for up to (3) three 28-day study cycles and evaluated for response or benefit. If benefit/response is achieved, azacitidine on days 1-7 and venetoclax on days 1-28 (or less if deemed necessary per protocol) will be given in repeating 28-day cycles until benefit/response is no longer achieved or until patient proceeds to transplantation.
The present invention provides systems and methods for monitoring in real time the physiological status of one or more subjects, especially subject engaged in potentially hazardous or dangerous activities. Systems include wearable items with one or more physiological sensors and a local data unit (LDU) operatively coupled to the sensors. The LDUs digitize and filter sensor data, extract physiological parameters, determine abnormal or not acceptable physiological conditions, and communicate to external monitoring facilities.  The external facilities display status and data concerning monitored subjects.  In preferred embodiments, communication between the LDUs and the external monitoring facilities dynamically adjusts to the condition of the subjects and to system changes such as subjects and external facilities entering and leaving and/or moving from place to place. The invention also provides program products for performing this invention's methods.
PURPOSE:To obtain a remedy for gastric ulcer containing a bacterium cell ingredient of Streptococcus haemolyticus having reduced toxicity as an active ingredient and exhibiting excellent action in cases difficult to treat especially for aged patients by conventional oral medication. CONSTITUTION:Living bacteria cells are suspended in a medium containing penicillin G, cephalosporim C or cycloserine, kept at 30-38 deg.C and then heat- treated at 40-50 deg.C to reduce the toxicity of bacteria cells. The resultant Strepto coccus haemolyticus (e.g. PCB-45 or OK-432) is used and formulated into an oral medicine or injection drug, preferably in locally administrating form to gastric mucosa to provide the aimed remedy. When the remedy is locally admin istrated to gastric mucosa, the dose is 0.01-1mg per adult/day based on the dried bacterium cell. The Streptococcus haemolyticus is A group Streptococcus pyogenes Su strain (e.g. ATCC 21060).